UBS raises target for uniQure stock from USD 27 to USD 48

Published on 10/27/2026 at 12:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UBS raised its target to USD 48 on October 14, 2026. uniQure stock costs EUR 19.60 on October 27, 2026 and Q2 revenue was USD 5.84 million.

Clinical data shape valuation

UBS lifted its uniQure target from USD 27.00 to USD 48.00 on October 14, 2026.
Second-quarter 2026 revenue reached USD 5.84 million, up from USD 5.26 million.
uniQure stock traded at EUR 19.60 at 12:40 p.m. CEST at Lang & Schwarz on October 27, 2026.

QURE, NL0010696654, Illustration mit AI erstellt.

uniQure N.V. (ISIN NL0010696654) traded at EUR 19.60 at Lang & Schwarz on October 27, 2026 at 12:40 p.m. CEST. The key valuation event was UBS raising its target from USD 27.00 to USD 48.00 on October 14, 2026, according to MarketScreener.

What supports the higher target?

The argument centers on AMT-130, uniQure's investigational gene therapy for Huntington's disease. The company said on September 29, 2026 that additional Phase I/II data showed continued slowing of disease progression, while the 48-month analysis showed a 44.00 percent slowing compared with 75.00 percent after 36 months, according to Gekko. The result keeps regulatory execution central to the investment case.

The latest operating comparison is more modest. In the second quarter of 2026, revenue reached USD 5.84 million, up from USD 5.26 million in the second quarter of 2025, while the quarterly loss was USD 1.22 per share. Those figures appear in the company's investor materials and are also summarized by uniQure.

Three dates frame the story

On July 29, 2026, uniQure reported second-quarter revenue of USD 5.84 million. On September 29, 2026, it presented the additional AMT-130 analysis with a 44.00 percent slowing figure. On October 14, 2026, UBS raised its target to USD 48.00 from USD 27.00 and maintained a Buy rating.

Which date comes next?

The next reported earnings date is November 9, 2026, before the market opens, according to Gekko. That report will give investors a fresh read on cash use, revenue and the clinical program after the analyst target revisions.

Stock trades ahead of results

For investors, the contrast is clear: UBS is valuing the regulatory opportunity more highly, while the latest reported revenue remains measured at USD 5.84 million. The upcoming earnings release therefore matters less for a single revenue comparison than for updates on AMT-130 and the path toward approval.

uniQure was trading at EUR 19.60 at Lang & Schwarz on October 27, 2026 at 12:40 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of QURE stock.